Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Enfortumab Vedotin for the Treatment of Locally Advanced, Unresectable, or Metastatic Castration-Resistant Prostate Cancer, ENCORE Study

Trial Status: active

This phase II trial tests whether enfortumab vedotin works to shrink tumors in patients with castration-resistant prostate cancer that has spread to nearby tissue or lymph nodes (locally advanced), cannot be removed by surgery (unresectable), or has spread to other places in the body (metastatic). Enfortumab vedotin is a type of drug called an antibody drug conjugate or ADC. ADCs are designed to combine antibodies (part of the immune system) and a drug (in this case a chemotherapy drug) to help target and kill specific kinds of cell. Enfortumab vedotin has been designed to target and kill cancer cells.